NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing

Provided By GlobeNewswire

Last update: Sep 11, 2025

TORONTO and HAIFA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to provide the following corporate updates.